Oppenheimer’s best small and mid-cap ideas for 2026
at seekingalpha.com (Tue, 6-Jan 11:59 AM)
Nurix’s Bexobrutideg Data Highlights Durable Responses and Optimal Dose Selection for Challenging CLL Cases
Market Chameleon (Mon, 8-Dec 10:33 AM)
Bexobrutideg Shows Strong and Durable Results in Relapsed or Refractory CLL: Phase 1 Trial Update from Nurix Therapeutics
Market Chameleon (Mon, 8-Dec 7:57 AM)
Nurix Secures $250 Million in Equity to Accelerate Drug Development—Pivotal Trials in CLL and Autoimmune Expansion in Focus
Market Chameleon (Mon, 27-Oct 11:18 AM)
NRIX’s $250 Million Registered Offering Draws Broad Investor Interest, Backing Ambitious Clinical Pipeline Expansion
Market Chameleon (Wed, 22-Oct 7:56 AM)
